MuSK cysteine-rich domain antibodies are pathogenic in a mouse model of autoimmune myasthenia gravis., PMID:40504622
MGBase: A Global, Observational Registry for Collaborative Research in Myasthenia Gravis., PMID:40468746
Myasthenia Gravis Presenting With Vocal Cord Paralysis As the Initial Symptom Occurring One Week Following Herpes Zoster Vaccination: A Case Report and Review of the Literature., PMID:40462824
The Role of Complement in the Pathogenesis and Treatment of Myasthenia Gravis., PMID:40422242
The Fusion Protein MuSK-Fc Functions as a Decoy to Block the Binding of Anti-MuSK Antibodies to MuSK., PMID:40411208
Myasthenia gravis with double-seropositive acetylcholine receptor and low-density lipoprotein receptor-related protein 4 antibodies combined with muscle atrophy: a case report and literature review., PMID:40356916
Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospects., PMID:40277145
[Treatment and clinical course of autoimmune myasthenia in Burkina Faso]., PMID:40248578
Long-Term Swallowing Rehabilitation for Muscle-Specific Tyrosine Kinase Antibody-Positive Myasthenia Gravis: A Case Report., PMID:40225522
Pyridostigmine-induced complete atrioventricular block in a patient with Musk antibody-negative myasthenia gravis a case report : Pyridostigmine-ind advanced AV block in MG patient with MuSK-neg., PMID:40148780
Efgartigimod for induction and maintenance therapy in muscle-specific kinase myasthenia gravis., PMID:40144041
Testing for Acetylcholine Receptor and Muscle-Specific Tyrosine Kinase Antibodies by Fixed Cell-Based Assay in Clinical Practice: Positive Predictive Value for Myasthenia Gravis., PMID:40130472
Efgartigimod improves non-AChR generalized Myasthenia Gravis: a real world experience., PMID:40128464
Clinical Spectrum and Therapeutic Outcome of Myasthenia Gravis in a Tertiary Care Hospital: A Retrospective Study., PMID:40087931
Prevalence and course of muscle-specific receptor tyrosine kinase (MuSK) antibodies in myasthenia gravis - A retrospective study., PMID:40086234
Efficacy and safety of different dosages of rituximab for myasthenia gravis: a single-arm meta-analysis., PMID:40085401
Successful treatment with refractory myasthenia gravis that developed after allogeneic hematopoietic stem cell transplantation: two case reports., PMID:40083543
Toward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable data., PMID:40069719
Development and Application of a Cell-Based Assay for Detecting Anti-Agrin Antibodies Associated With Myasthenia Gravis., PMID:40065451
A Case of Myasthenia Gravis: A Paraneoplastic Syndrome or an Immune-Related Disorder?, PMID:40062097
Double-seropositive Myasthenia Gravis Following COVID-19., PMID:40058857
Prevalence and incidence rates of 17 neuromuscular disorders: An updated review of the literature., PMID:40034005
Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension., PMID:40034001
Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions., PMID:40033991
Unusual presentations of myasthenia gravis and misdiagnosis., PMID:40032968
Efficacy and safety of rituximab in anti-MuSK myasthenia Gravis: a systematic review and meta-analysis., PMID:40021769
Young child with MuSK myasthenia gravis: treatment and remission with rituximab., PMID:40000033
Clinical Outcomes of Rituximab Infusion Among Refractory Myasthenia Gravis Patients in the Philippines: A 10-Year Retrospective Study., PMID:39991399
Autoantibodies in myasthenia gravis: cluster analysis and clinical correlations., PMID:39968461
Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer models., PMID:39898046
Orbicularis Oculi Stimulated Jitter Analysis in Children With Autoimmune Myasthenia Gravis., PMID:39887421
Concomitant Exacerbation of Graves Orbitopathy and Double-Seronegative Myasthenia Gravis after SARS-CoV-2 Infection., PMID:39882352
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial., PMID:39862880
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study., PMID:39862879
Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study., PMID:39839222
Advances in Disease-Modifying Therapeutics for Chronic Neuromuscular Disorders., PMID:39708835
A clinical perspective on muscle specific kinase antibody positive myasthenia gravis., PMID:39703505
Advances in B Cell Targeting for Treating Muscle-Specific Tyrosine Kinase-Associated Myasthenia Gravis., PMID:39678139
Efgartigimod treatment in patients with anti-MuSK-positive myasthenia gravis in exacerbation., PMID:39628891
Surgical treatment of thymic epithelial tumor and myasthenia gravis., PMID:39624461
Telitacicept in combination with B-cell depletion therapy in MuSK antibody-positive myasthenia gravis: a case report and literature review., PMID:39624088
McHDV VP60 Virus-like Particles Elicit Protective Immunity Against Moschus chrysogaster Hemorrhagic Disease in Rabbits., PMID:39599478
Long-term efficacy and safety of tacrolimus in anti-MuSK antibody-positive myasthenia gravis: a retrospective single-center cohort study., PMID:39503950
Complications of Long COVID: Unraveling a Case of Very-Late-Onset Myasthenia Gravis., PMID:39479090
Isolated Respiratory Failure as the Presenting Symptom of Muscle-Specific Kinase Myasthenia Gravis: A Case Report and Literature Review., PMID:39474296
[Efficacy and safety of rituximab in the treatment of pediatric myasthenia gravis]., PMID:39429076
Clinical Characteristics of Double Seropositive Myasthenia Gravis., PMID:39428782
275th ENMC international workshop: Seronegative myasthenia gravis: An update paradigm for diagnosis and management, 9-11 February 2024, Hoofddorp, the Netherlands., PMID:39427494
Laryngeal Myasthenia Gravis in Voice Patients: Clinical, Serologic, and Neuromuscular Characterization of Seronegative Patients for Antibodies Against the Acetylcholine Receptor and Muscle-Specific Kinase., PMID:39419706
Efficacy and safety of low-dose rituximab in the treatment of myasthenia gravis: a systemic review and meta-analysis., PMID:39385818